Alpha-1 antitrypsin deficiency alleles and severe cystic fibrosis lung disease
- PMID: 10195072
- PMCID: PMC1745129
- DOI: 10.1136/thx.53.12.1022
Alpha-1 antitrypsin deficiency alleles and severe cystic fibrosis lung disease
Abstract
Background: Alpha-1 antitrypsin (alpha 1-AT) is the most abundant proteinase inhibitor within the lung. We have recently reported the surprising observation that cystic fibrosis patients with mild to moderate deficiency of alpha 1-antitrypsin have significantly better pulmonary function than non-deficient patients. This study may have been biased as it did not include the most severely affected patients who have died in childhood or those who have undergone orthotopic lung transplantation. The prevalence of alpha 1-antitrypsin deficiency alleles in this most severely affected group of patients with cystic fibrosis was therefore assessed.
Methods: DNA was obtained from neonatal blood spots from children with cystic fibrosis who had died from pulmonary disease and from formalin fixed lung tissue from transplanted cystic fibrosis patients. The common S and Z deficiency alleles of alpha 1-AT were sought by amplification mutagenesis of the appropriate region of the alpha 1-AT gene followed by restriction enzyme digestion with Xmn I and Taq I, respectively.
Results: Seventy-nine patients were identified (seven dead, 72 transplanted). Two patients (2.5%) were heterozygous for the Z allele of alpha 1-AT and four (5.1%) were heterozygous for the S allele. This is not significantly different from the incidence in the normal population of 4% and 8% for the S and Z alleles, respectively.
Conclusions: These data support previous findings that deficiency of alpha 1-AT is not associated with more severe pulmonary disease in cystic fibrosis and may be associated with milder lung disease. Further work is needed to clarify the mechanisms underlying the progressive lung damage in cystic fibrosis.
Similar articles
-
Alpha1-antitrypsin deficiency alleles and the Taq-I G-->A allele in cystic fibrosis lung disease.Eur Respir J. 1998 Apr;11(4):873-9. doi: 10.1183/09031936.98.11040873. Eur Respir J. 1998. PMID: 9623690
-
[Association between alpha 1 antitrypsin deficiency and cystic fibrosis severity].J Pediatr (Rio J). 2005 Nov-Dec;81(6):485-90. doi: 10.2223/JPED.1423. J Pediatr (Rio J). 2005. PMID: 16385367 Portuguese.
-
Alpha 1-antitrypsin deficiency alleles in cystic fibrosis lung disease.Am J Respir Cell Mol Biol. 2003 Sep;29(3 Pt 1):390-6. doi: 10.1165/rcmb.2002-0271OC. Epub 2003 Apr 14. Am J Respir Cell Mol Biol. 2003. PMID: 12689922
-
Alpha-1 Antitrypsin Therapy in Cystic Fibrosis and the Lung Disease Associated with Alpha-1 Antitrypsin Deficiency.Ann Am Thorac Soc. 2016 Apr;13 Suppl 2:S191-6. doi: 10.1513/AnnalsATS.201504-245KV. Ann Am Thorac Soc. 2016. PMID: 27115956 Review.
-
Alpha-1 antitrypsin deficiency with severe pulmonary emphysema.Intern Med. 2004 Mar;43(3):223-6. doi: 10.2169/internalmedicine.43.223. Intern Med. 2004. PMID: 15098605 Review.
Cited by
-
The C264Y missense mutation in the extracellular domain of L1 impairs protein trafficking in vitro and in vivo.J Neurosci. 2003 Jan 1;23(1):277-86. doi: 10.1523/JNEUROSCI.23-01-00277.2003. J Neurosci. 2003. PMID: 12514225 Free PMC article.
-
Genetic influences on cystic fibrosis lung disease severity.Front Pharmacol. 2013 Apr 23;4:40. doi: 10.3389/fphar.2013.00040. eCollection 2013. Front Pharmacol. 2013. PMID: 23630497 Free PMC article.
-
Bioinformatic analysis of pathogenic missense mutations of activin receptor like kinase 1 ectodomain.PLoS One. 2011;6(10):e26431. doi: 10.1371/journal.pone.0026431. Epub 2011 Oct 18. PLoS One. 2011. PMID: 22028876 Free PMC article.
-
Elevation of hepatic sulphotransferase activities in mice with resistance to cystic fibrosis.Biochem J. 2002 May 15;364(Pt 1):115-20. doi: 10.1042/bj3640115. Biochem J. 2002. PMID: 11988083 Free PMC article.
-
Disease modifying genes in cystic fibrosis: therapeutic option or one-way road?Naunyn Schmiedebergs Arch Pharmacol. 2006 Nov;374(2):65-77. doi: 10.1007/s00210-006-0101-2. Epub 2006 Oct 11. Naunyn Schmiedebergs Arch Pharmacol. 2006. PMID: 17033796 Review.
References
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical